"10.1371_journal.pone.0148170","plos one","2016-02-22T00:00:00Z","Micaela Johanna Glat; Tali Ben-Zur; Yael Barhum; Daniel Offen","Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv, Israel; Felsenstein Medical Research Center, Sackler School of Medicine, Tel-Aviv University, Petach Tikva, Israel","Conceived and designed the experiments: MG DO. Performed the experiments: MG YB TB. Analyzed the data: MG DO TB YB. Contributed reagents/materials/analysis tools: MG YB TB. Wrote the paper: MG DO.","DO (with others) has submitted several patent applications related to ND-13, some of which have already been granted. All were assigned to “Ramot at Tel Aviv University” and licensed to \"UGH Pharma, Inc.\" Patent name: \"A method of selecting peptides derived from the DJ-1 protein, certain selected peptides and their use for the treatment of neurodegenerative diseases\" and number: 8,378,070. Patent name: \"Neuroprotective peptides for increasing the viability of cells under oxidative stress conditions and as a result, for the treatment of neurodegenerative diseases.\" and number: 8,212,001. Pending patent name: \"Use of neuroprotective peptides for the treatment of inflammatory diseases\" and number: 61/889,112. Pending patent name: \"Combination therapy for the treatment of oxidative stress and related disorders and inflammatory diseases\" and number: 61/904,066. DO is a consultant to “Brainstorm Cell Therapeutics”. The authors confirm that the patents relating to materials pertinent to this article do not alter their adherence to all PLOS ONE policies on sharing data and materials. The other authors have nothing to disclose.","2016","02","Micaela Johanna Glat","MJG",4,TRUE,2,3,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
